PEG 40-Uricase
Hyperuricemia (e.g., Refractory Gout, Tumor Lysis Syndrome)
Pre-clinicalActive
Key Facts
Indication
Hyperuricemia (e.g., Refractory Gout, Tumor Lysis Syndrome)
Phase
Pre-clinical
Status
Active
About Mountain View Pharmaceuticals
Mountain View Pharmaceuticals is a private, clinical-stage biotech focused on applying advanced PEGylation chemistry to create improved therapeutics for rare and metabolic diseases. The company's core intellectual property is its 'Better PEGs' platform, designed to optimize drug delivery. While specific pipeline details are not fully public, its lead asset is PEG 40-Uricase, indicating a focus on conditions like refractory gout. The company operates through partnerships and appears to be in a pre-revenue or early development stage.
View full company profile